# Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation

> **NCT01680185** · PHASE3 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 85 (actual)

## Conditions studied

- Hyperglycemia

## Interventions

- **DRUG:** Insulin lispro, Humalog (Eli Lilly) in insulin pump
- **DRUG:** Human insulin isophane, Humulin N (Eli Lilly)
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT01680185
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01680185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01680185, "Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01680185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*